| Recruiting | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) NCT07405164 | Merck Sharp & Dohme LLC | Phase 3 |
| Enrolling By Invitation | Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease NCT05737602 | Massachusetts General Hospital | N/A |
| Recruiting | Institutional Registry of Rare Diseases NCT06573723 | Hospital Italiano de Buenos Aires | — |
| Withdrawn | MSD Belzutifan PAS NCT06554730 | Merck Sharp & Dohme LLC | — |
| Recruiting | Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial NCT07167329 | José Claudio Casali da Rocha | Phase 2 |
| Recruiting | Data Collection Protocol for Patients With Von Hippel Lindau Disease NCT05955014 | M.D. Anderson Cancer Center | — |
| Recruiting | Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells NCT06194669 | IRCCS San Raffaele | — |
| Unknown | 68Ga-NY104 PET/CT in Von Hippel-Lindau Disease NCT05810246 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | A Study of BPI-452080 in Subjects With Solid Tumors NCT05843305 | Betta Pharmaceuticals Co., Ltd. | Phase 1 |
| Recruiting | Propranolol and Von Hippel-Lindau Disease NCT05424016 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients NCT06523582 | Universidad Nacional Autonoma de Mexico | — |
| Recruiting | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocr NCT04924075 | Merck Sharp & Dohme LLC | Phase 2 |
| Active Not Recruiting | Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma NCT04458935 | National Eye Institute (NEI) | — |
| Recruiting | Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors NCT04074135 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Drivers of Hypoxia-induced Angiogenesis in Tumor Development NCT03979833 | University of Copenhagen | — |
| Completed | MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK NCT03108066 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Recruiting | Familial Investigations of Childhood Cancer Predisposition NCT03050268 | St. Jude Children's Research Hospital | — |
| Completed | Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) NCT02108002 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 |
| Recruiting | MyVHL: Patient Natural History Study NCT03749980 | Joshua Mann, MPH | — |
| Recruiting | Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients NCT02420067 | Marie Luise Bisgaard, MD | — |
| Completed | Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease NCT01168440 | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Phase 2 |
| Terminated | Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease NCT01015300 | Dartmouth-Hitchcock Medical Center | EARLY_Phase 1 |
| Completed | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease NCT00970970 | University Medical Center Groningen | — |
| Completed | Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Ma NCT00470977 | Manhattan Eye, Ear & Throat Hospital | Phase 1 / Phase 2 |
| Enrolling By Invitation | Use of Tracking Devices to Locate Abnormalities During Invasive Procedures NCT00102544 | National Institutes of Health Clinical Center (CC) | N/A |
| Completed | Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease NCT00062166 | National Cancer Institute (NCI) | — |
| Completed | Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 NCT00052013 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Precision Medicine for Neurocutaneous Syndromes in Western China NCT07327164 | West China Hospital | — |
| Terminated | Von Hippel-Lindau Disease Genetic Epidemiology Study NCT00001803 | National Cancer Institute (NCI) | — |